Interestingly, not only naïve but also tumor-reactive TILs can be metabolically manipulated with AKT inhibitors during in vitro expansion, resulting in a memory-like phenotype and increased antitumor activity upon allogeneic transplantation into immune-deficient, multiple myeloma-bearing mice [178, 181]. This evidence concerns the gene AKT1 and neoplasm.